26 GLP-1 Cost Statistics 2027

Current pricing data, insurance coverage trends, and affordability insights to help women understand GLP-1 medication costs and evaluate physician-guided weight management options in 2027.

Short answer

Median annual out-of-pocket spending on GLP-1 medications was $1,528 per user, and nearly one in five users spent at least 10% of household income. Coverage is limited: 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026, and 43% of employers with 5,000 or more workers covered them primarily for weight loss in 2025.

Majesta HealthReviewed by Ksenia Petrushkina, PA-C
Published Reviewed 14 min read

Current pricing data, insurance coverage trends, and affordability insights to help women understand GLP-1 medication costs and evaluate physician-guided weight management options in 2027.

The GLP-1 weight loss medication market is experiencing a dramatic cost transformation heading into 2027. With brand-name list prices historically exceeding $1,300 monthly, understanding your options has never been more important. For women seeking transparent, physician-guided care, platforms like Majesta Health publish all-inclusive pricing for compounded GLP-1 treatment plans starting at $159 for the first month, then $289 monthly.

This statistics report breaks down the costs, coverage realities, and market shifts shaping GLP-1 affordability in 2027. It draws on research from KFF, the CDC, federal healthcare agencies, and published medical studies.

Key Takeaways

  • Insurance coverage remains limited: Only 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026.
  • Women lead adoption: Women were more likely than men to currently use GLP-1 medications (15% versus 9%) in a 2025 KFF survey.
  • Out-of-pocket costs burden patients: Median annual spending was $1,528 per user, with nearly one in five spending at least 10% of household income.
  • Employer coverage varies: In 2025, 43% of employers with at least 5,000 workers covered GLP-1 medications primarily for weight loss.
  • Transparent telehealth pricing exists: Published treatment-plan prices can help patients understand physician consultation, medication, shipping, and ongoing support costs.

Understanding Weight Loss Drug Costs in 2027

The landscape of GLP-1 medications

The GLP-1 receptor agonist category has become a major pharmaceutical segment. These medications, which include semaglutide formulations, work by mimicking natural hormones that help regulate appetite and blood sugar. Tirzepatide acts on both GLP-1 and GIP receptors.

Costs depend on the prescribed medication, insurance coverage, eligibility for assistance programs, and the pharmacy or provider involved.

1. 12% of US adults currently use GLP-1 medications

A March 2026 KFF Health Tracking Poll found that 12% of US adults were currently taking GLP-1 medications for weight loss or chronic health conditions.

The percentage represented current use across several medical indications, including diabetes and cardiovascular conditions.

The finding remained unchanged from November 2025, although current use had increased from 6% in May 2024.

2. 18% of US adults have ever taken GLP-1 medications

KFF's March 2026 polling found that 18% of adults had taken a GLP-1 medication at some point.

This measure includes current and former users, regardless of whether the medication was prescribed for weight management or another condition.

The figure was unchanged from November 2025, indicating that overall reported use had remained relatively stable between those surveys.

3. Women are more likely to use GLP-1 medications

Women were more likely than men to report currently taking GLP-1 medication, with 15% of women versus 9% of men using these treatments.

The figures came from KFF's October-November 2025 survey of American adults.

These findings cover medications prescribed for several medical purposes, not exclusively weight loss.

4. Adults ages 50–64 report the highest usage at 22%

Adults ages 50 to 64 reported the highest GLP-1 use across age groups at 22%, compared to 9% among adults ages 65 and older.

The survey measured current medication use in late 2025.

The figures include treatment for diabetes and other chronic conditions alongside weight management.

GLP-1 usage measureReported figurePopulationSurvey period
Currently using12%US adultsMarch 2026
Ever used18%US adultsMarch 2026
Women currently using15%US womenLate 2025
Ages 50–64 currently using22%US adults ages 50–64Late 2025

GLP-1 Injection Medication Costs: What to Expect

5. Medicare GLP-1 Bridge offers a $50 monthly copay

Eligible Medicare Part D beneficiaries can access certain GLP-1 medications through the Medicare GLP-1 Bridge with a $50 monthly copay.

The demonstration began July 1, 2026, and is scheduled to continue through December 31, 2027.

Eligibility requirements apply, and the program does not provide automatic coverage for every Medicare beneficiary or every GLP-1 medication.

Majesta's Transparent GLP-1 Pricing for Women

For women seeking an alternative to complex insurance requirements and variable brand-name pricing, compounded GLP-1 options represent a different treatment category.

Majesta publishes all-inclusive pricing with no separate membership or enrollment fees. An independent licensed physician must determine whether a compounded prescription is clinically appropriate.

Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any FDA-approved medication.

No hidden fees: Majesta's commitment to clarity

Majesta's Essential Plan (Compounded Semaglutide/Glycine/B12 Injection) costs $159 for the first month, then $289 monthly. The Performance Plan (Compounded Tirzepatide/Glycine/B12 Injection) costs $269 for the first month, then $399 monthly.

Both plans include the $20 physician consultation, monthly physician check-ins, care-team messaging, medication if prescribed, and 2-day shipping. Pharmacy preparation time is separate.

Tailored support for women's weight management

Majesta specifically focuses on women's health, with a clinical approach that acknowledges the unique challenges of weight management during perimenopause and menopause.

The care team includes independent US-licensed physicians with publicly verifiable credentials.

Treatment decisions depend on medical history, clinical appropriateness, and physician review rather than a patient's preference for a particular medication.

Women's GLP-1 Use and Treatment Access

6. Women are 1.5 times more likely to consider GLP-1s

Women were approximately 1.5 times more likely than men to consider GLP-1 medication for weight loss, with 27% versus 18% expressing interest.

KFF surveyed adults who were not currently taking these medications in late 2025.

Interest does not establish medical eligibility or indicate that respondents would necessarily obtain a prescription.

7. 76% of GLP-1 users obtained medication from a doctor

In KFF's 2025 survey, 76% of respondents who had taken GLP-1 medication said they obtained it from one of their doctors.

The question covered both current and former users.

The reported source of medication does not independently establish whether every prescription was written for weight loss or another medical indication.

8. 17% of GLP-1 users obtained medication online

Approximately 17% of respondents who had used GLP-1 medications reported obtaining them through an online provider or website.

The finding comes from KFF's late-2025 national survey.

The survey did not establish whether every online service involved an appropriately licensed prescribing clinician or pharmacy.

Insurance Coverage for GLP-1 Weight Loss Medications

9. Only 13 state Medicaid programs covered GLP-1s for obesity

As of January 2026, only 13 state Medicaid programs covered GLP-1s for obesity treatment under fee-for-service.

Medicaid coverage requirements differ depending on whether the medication is prescribed for obesity or another medically accepted indication.

Even when obesity medications are covered, prior authorization and other requirements may limit access.

10. Medicaid GLP-1 prescriptions increased sevenfold

Medicaid prescriptions for GLP-1 medications increased from approximately 1 million to over 8 million between 2019 and 2024.

KFF analyzed federal Medicaid drug utilization records covering approved GLP-1 medications and tirzepatide.

These prescription totals include treatment for diabetes and other indications and do not represent unique patients receiving obesity treatment.

11. Medicaid spending reached almost $9 billion in 2024

Medicaid gross spending on GLP-1 medications increased from approximately $1 billion to almost $9 billion between 2019 and 2024.

These amounts represent spending before manufacturer rebates.

Consequently, gross expenditure figures should not be interpreted as the final net amount paid by Medicaid programs.

12. GLP-1s represented over 8% of Medicaid drug spending

GLP-1 medications accounted for over 8% of Medicaid prescription drug spending before rebates in 2024, up from approximately 1% in 2019.

The figures include medications used for diabetes and other approved conditions.

This spending share differs from the proportion of Medicaid patients receiving GLP-1 prescriptions.

13. Gross Medicaid spending reached $1,000 per prescription

KFF reported approximately $1,000 in gross spending per Medicaid GLP-1 prescription in 2024.

The calculation covers multiple medications and indications rather than a particular obesity treatment.

It also excludes manufacturer rebates and does not represent a patient's out-of-pocket payment or a standardized monthly treatment price.

14. Ozempic accounted for 39% of Medicaid GLP-1 prescriptions

In 2024, Ozempic represented 39% of Medicaid GLP-1 prescriptions, becoming the largest individual medication category in KFF's analysis.

Ozempic is approved for type 2 diabetes and certain additional indications, not specifically for weight loss.

The figure therefore should not be interpreted as the proportion of obesity prescriptions attributable to Ozempic.

Medicaid measure20192024
GLP-1 prescriptionsAbout 1 millionOver 8 million
Gross GLP-1 spendingAbout $1 billionAlmost $9 billion
Share of prescription spendingAbout 1%Over 8%

Employer Coverage and GLP-1 Affordability

15. 43% of very large employers cover GLP-1s

In 2025, 43% of employers with at least 5,000 workers covered GLP-1 medications when used primarily for weight loss.

KFF measured coverage offered through employer health benefit plans.

The figure applies to employers within this workforce category, not to all insured workers or all US employers.

16. Employer coverage rose from 28% to 43%

Among employers with at least 5,000 workers, GLP-1 coverage for weight loss increased from 28% to 43% between 2024 and 2025.

These figures reflect employers reporting coverage through their largest health plan.

The findings do not indicate that every eligible employee could obtain medication without authorization requirements or cost-sharing.

17. 66% of very large employers report significant spending impact

Among employers with at least 5,000 workers that covered GLP-1 medications primarily for weight loss, 66% reported a significant impact on prescription drug spending.

The finding came from KFF's 2025 Employer Health Benefits Survey.

It measures employers' reported spending impact rather than an independently calculated increase in total healthcare expenditure.

18. Only 19% of large employers cover GLP-1s for weight loss

Just 19% of US firms with at least 200 workers that offered health benefits reported coverage for GLP-1 medications used primarily for weight loss in 2025.

This overall percentage includes employers across different workforce sizes, all with at least 200 workers.

Coverage was more common among employers with at least 5,000 workers than among smaller firms.

19. 34% of employers require additional lifestyle support

Among employers covering GLP-1 medications for weight loss, 34% required participation in additional support to receive coverage.

Requirements included meeting with a dietitian, case manager, or therapist, or participating in a lifestyle program.

KFF reported this finding in its 2025 employer survey, illustrating differences in conditions attached to coverage.

Employer sizeGLP-1 coverage for weight lossSurvey year
200–999 workers16%2025
1,000–4,999 workers30%2025
5,000+ workers43%2025
All firms with 200+ workers19%2025

Understanding Out-of-Pocket GLP-1 Costs

20. Median annual out-of-pocket spending reached $1,528

Median out-of-pocket spending per GLP-1 user reached $1,528 annually, according to research published in the Journal of General Internal Medicine in July 2026.

Researchers examined US Medical Expenditure Panel Survey data collected between 2013 and 2023.

The analysis included GLP-1 and related incretin medications used for multiple indications, rather than exclusively obesity treatment.

21. Nearly 1 in 5 users faced high medication spending burdens

Approximately 18.18% of GLP-1 users spent at least 10% of their annual household income out of pocket on these medications.

The researchers classified this level as a high out-of-pocket financial burden.

The study covered data from 2013 through 2023 and included users receiving medications for several clinical indications.

22. Average GLP-1 spending represented 7.04% of household income

The same study found that out-of-pocket GLP-1 expenses averaged 7.04% of annual household income among users.

Financial burden was greatest among uninsured, publicly insured, and lower-income populations.

This percentage measures the average income share spent on medications, not the average prescription price or insurance reimbursement.

23. National GLP-1 spending reached $64.9 billion in 2023

Total US spending on GLP-1 and related incretin medications increased from $4.4 billion in 2013 to $64.9 billion in 2023.

Researchers reported a nearly fifteenfold increase over the study period.

The estimate includes total medication expenditure across payers, rather than patients' out-of-pocket costs alone.

Understanding Side Effects and Value in Weight Loss Treatments

24. 26.5% of adults with diabetes used injectable GLP-1s

In 2024, 26.5% of adults with diagnosed diabetes reported using injectable GLP-1 medications to lower blood sugar or lose weight.

The CDC published the findings in its July 2025 National Center for Health Statistics data brief.

The statistic concerns adults with diagnosed diabetes and cannot be generalized to all US adults receiving obesity treatment.

25. Injectable GLP-1 use was higher among adults with diabetes and obesity

Injectable GLP-1 use was 32.4% among adults with diagnosed diabetes and obesity, compared with 16.7% among those with diabetes and a healthy weight.

The CDC analyzed survey data collected during 2024.

The findings describe medication use by body mass index category, not differences in treatment effectiveness or medication affordability.

26. One in three adults ages 50–64 with diabetes used GLP-1 injectables

Among adults with diagnosed diabetes, 33.3% of those ages 50–64 reported using injectable GLP-1 medication.

The CDC published this finding using 2024 survey data.

The result applies specifically to adults with diagnosed diabetes and includes medication use for blood sugar management or weight loss.

The Importance of Physician-Guided Treatment

GLP-1 treatment decisions require an individualized medical assessment. A licensed prescribing clinician should review relevant contraindications, treatment goals, medication history, and potential interactions.

The FDA advises that compounded medications should generally be considered only when an individual patient's medical needs cannot be met by an FDA-approved medication.

Majesta's LegitScript-certified platform connects patients with independent physicians for treatment assessment and follow-up. The platform's care model includes monthly physician check-ins for its injection plans, subject to physician approval and enrollment availability.

Cost-Saving Strategies and Patient Assistance Programs

Insurance coverage remains inconsistent, particularly when GLP-1 medications are prescribed primarily for obesity.

Patients can review their plan's formulary, prior authorization requirements, manufacturer assistance eligibility, and applicable federal programs. Their prescribing clinician can help clarify medically appropriate treatment options.

For patients considering compounded medication, the FDA's compounding guidance explains important safety and regulatory distinctions. A lower price alone does not establish a medical need for compounding.

Why Majesta Matters When Comparing GLP-1 Costs in 2027

GLP-1 pricing is changing, but understanding the total cost of treatment remains essential. Insurance restrictions, introductory rates, and separate provider fees can make comparisons difficult. Women considering physician-guided weight management deserve clear information before making a financial or medical commitment.

Majesta focuses on transparent pricing and independent physician oversight, with a care model designed around women's health needs.

Its plans include:

  • Essential: $159 for the first month, then $289 monthly for compounded semaglutide/glycine/B12 injections.
  • Performance: $269 for the first month, then $399 monthly for compounded tirzepatide/glycine/B12 injections.
  • Express (planned): Proposed $249 for the first approved 30-day care cycle, then $339 per approved 30-day care cycle for compounded tirzepatide LPT® chewable tablets. Not yet available.
  • Physician oversight: An independent US-licensed physician reviews medical history and determines treatment appropriateness.
  • Included services: Physician consultation, monthly check-ins, care-team messaging, and medication and shipping when prescribed and approved.
  • Transparent terms: No separate membership fees, with payment collected only after physician approval.

The platform does not offer FDA-approved brand-name medications or bill insurance. Its compounded preparations have not undergone FDA approval.

As enrollment becomes available, women can review the plan details and consider whether the care model fits their needs.

Start your assessment to explore the physician-review process and early-access options. Completing an assessment does not guarantee treatment or a prescription.

Before You Change Anything

Discuss your medical history, current medications, pregnancy plans, and possible contraindications with a licensed healthcare professional before considering GLP-1 medication. If you are pregnant, planning pregnancy, or using hormonal contraception, ask about medication-specific precautions.

FDA-approved semaglutide and tirzepatide products carry important warnings and contraindications. The prescribing clinician should review these with you, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Do not independently start, stop, or change medication without guidance from your prescribing clinician.

When to Get Help Right Away

Seek urgent medical attention for severe or persistent abdominal pain, especially when accompanied by vomiting. These symptoms may indicate pancreatitis or another serious medical problem requiring evaluation.

Call 911 for chest pain, difficulty breathing, fainting, or signs of a severe allergic reaction, such as swelling of the face, lips, tongue, or throat.

Contact your prescribing clinician promptly about persistent vomiting, dehydration, severe gastrointestinal symptoms, or other concerning treatment-related effects.

This article is for informational purposes only and does not constitute medical advice, diagnosis or treatment. It does not recommend starting, stopping or changing any medicine.

Sources checked November 20, 2026.

Frequently Asked Questions

How much do GLP-1 weight loss medications cost per month in 2027?

Costs vary by medication, insurance coverage, and eligibility for assistance programs. Novo Nordisk's announced $675 monthly list price for certain products takes effect January 1, 2027. Eligible Medicare GLP-1 Bridge participants may pay $50 monthly. Majesta's company-confirmed compounded injection-plan pricing ranges from $289 to $399 monthly after introductory pricing, subject to physician approval and enrollment availability.

Does insurance cover GLP-1 medications for weight loss?

Coverage remains inconsistent. As of January 2026, 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service. Employer coverage also varies considerably. Patients should check their specific insurance benefits, medication indications, and prior authorization requirements.

What are the differences in cost between injectable and oral GLP-1 medications?

Prices depend on the medication, formulation, insurance coverage, and payment arrangement. Oral and injectable products should not be assumed to have identical costs or clinical characteristics. A physician can discuss which FDA-approved treatment options are medically appropriate.

How does Majesta's pricing compare to other GLP-1 telehealth providers?

Majesta's company-confirmed Essential and Performance plans have recurring prices of $289 and $399 monthly, respectively, following their introductory months. These plans include physician consultation, monthly check-ins, prescribed medication when approved, and shipping. Comparisons with other providers should account for membership charges, medication type, and billing frequency.

Are compounded GLP-1 medications a more affordable option, and are they safe?

Compounded medications may have different pricing structures, but lower cost alone is not a medical justification for their use. Compounded medications are not FDA-approved as final products and have not undergone FDA review for safety, effectiveness, or quality before marketing. A licensed physician should determine whether a patient has a medical need that cannot be met by an FDA-approved product.

Sources

  1. 1.KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use · KFF · accessed
  2. 2.Public Opinion on Prescription Drugs and Their Prices · KFF · accessed
  3. 3.Medicaid Coverage of and Spending on GLP-1s · KFF · accessed
  4. 4.2025 Employer Health Benefits Survey · KFF · accessed
  5. 5.Use of GLP-1 Receptor Agonist Medications Among Adults With Diagnosed Diabetes · CDC, National Center for Health Statistics · accessed
  6. 6.Spending and Affordability of Glucagon-Like Peptide-1 Receptor Agonists and Other Incretin Mimetics in the United States, 2013–2023 · Journal of General Internal Medicine · accessed
  7. 7.Wegovy and Ozempic List Price Reduction · Novo Nordisk · accessed
  8. 8.Medicare GLP-1 Bridge · Centers for Medicare & Medicaid Services · accessed
  9. 9.FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss · U.S. Food and Drug Administration · accessed

Ready to Join Early Access?

Join the early access list and we will email you when enrollment opens.

Start Your Assessment